EADO 2020 | Neoadjuvant approaches in melanoma

Alexander van Akkooi • 14 Oct 2020

Melanoma Skin Cancer

Immuno-Oncology

Alexander van Akkooi, MD, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands, gives an update on neoadjuvant approaches in treating melanoma. Dr Akkooi discusses the benefits of neoadjuvant immunotherapy and targeted therapy. This is interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Real-world use of t-vec in unresectable stage IIIB-IvM1a melanoma

Alexander van Akkooi • 14 Oct 2020

Serum NSE levels as a biomarker in MCC

Alexander van Akkooi • 19 Apr 2021

Sentinel node tumor burden for prognostication in melanoma

Alexander van Akkooi • 19 Apr 2021

Real-world analysis of T-VEC for melanoma

Alexander van Akkooi • 19 Apr 2021

Related Videos

Clinical trial updates on patient responses with triplet therapy

Jeffrey Weber • 4 Jan 2019

Grant McArthur on the 3 positive melanoma trials presented at the ESMO 2017 Congress

Grant McArthur • 11 Sep 2017

The PLATforM trial: clinical updates on spartalizumab antibody treatment

Jeffrey Weber • 4 Jan 2019

Combination targeted adjuvant therapy doubles relapse-free survival in stage III melanoma

Axel Hauschild • 11 Sep 2017